CF PharmTech Inc. held its first extraordinary general meeting of 2025 on December 16. Shareholders approved the Share Repurchase Mandate, the proposed adoption of the H Share Award Scheme, and the authorization for the Board and authorized persons to handle matters related to the H Share Award Scheme. All proposals were passed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251216-11957639), on December 16, 2025, and is solely responsible for the information contained therein.
Comments